Third Rock Ventures has appointed Daniel Lynch as an entrepreneur-in-residence (EIR). In his new role at the venture capital firm, Lynch will provide strategic input on new and existing portfolio companies.
At present, he serves as executive chairman of Avila Therapeutics and Stromedix and on the board of directors for Third Rock Ventures’ portfolio company, bluebird bio. Lynch was previously working with ImClone Systems as CEO and CFO.
Click here for the release from Third Rock Ventures.